SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

Add KTOV Price Alert      Hide Sticky   Hide Intro
Moderator: Sugarplum, ash111, BostonBull1990, TradeFlow, whan7
Search This Board:
Last Post: 10/21/2016 5:35:28 PM - Followers: 129 - Board type: Free - Posts Today: 0


US Office

1615 Suter’s Lane NW, Washington DC 20007, Tel:  +1-202-965-2215

Israel Office

One Azrieli Center, Round Tower, Tel Aviv 6701101


Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs
that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Kitov is developing combination drug products that treat the pain of osteoarthritis without causing cardiovascular problems.
These drugs will not only not need to be labeled with health warnings, but will actually be labeled as reducing the risk of
cardiovascular events. Kitov’s drugs have the potential to improve the health of millions of patients worldwide.
It is expected that physicians will prefer to prescribe them rather than prescribe two separate drugs, to improve their patients’ health and to reduce their own legal exposure.

Kitov is currently focusing two late-stage drugs. Both contain NSAIDs that are widely consumed throughout the world for treating osteoarthritis.
Each of Kitov’s drugs adds to the NSAID a second drug product that reduces hypertension.

KIT-301: Naproxen combined with anti-hypertension. Ready for phase III clinical trial. New Drug Application (NDA) scheduled
for 20-24 months from start of development.
KIT-302: Celecoxib combined with anti-hypertension. Ready for phase III clinical trial. New Drug Application (NDA) scheduled for 2015.

Osteoarthritis, affecting approximately half of all adults over the age of 50, is a degenerative disease of joints that can cause pain and limit mobility.
Exercise and weight control are important therapies for controlling symptoms, but for many patients medication is the next step in pain treatment.
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used medications for treating osteoarthritis pain.
However, these medications raise blood pressure (hypertension) and thereby increase the risk of heart attacks, strokes, and death.
This has led the US FDA to require including a black box warning in the labeling of all NSAIDs, warning of these increased cardiovascular risks.


Dr. John Paul Waymack – M.D., Sc.D.

Chairman of the Board of Directors and Chief Medical Officer

Dr. Waymack was one of the founders of Kitov Pharmaceuticals and has served as the Chairman of our Board of Directors and Chief Medical Officer since July 2013. Dr. Waymack has over 20 years of experience in the biopharma field. Dr. Waymack is a former academic transplant surgeon and a former FDA medical officer, with over fifteen years of experience in drug development as a consultant to major pharmaceutical companies, including Pfizer, Roche, Pharmacia, Warner Lambert and Searle. During his 10 years of academic career, Dr. Waymack published over 100 scientific essays, mainly in the fields of prostaglandins and immunology. In addition, Dr. Waymack volunteered to the U.S. army, where he was commissioned and served as a Major in the Medical Corp. in the position of Chief of Surgical Research in the U.S. Army’s Institute for Surgical Research. Dr. Waymack was also an associate professor of surgery at the University of Texas Medical Branch and at the University of Medicine and Dentistry of New Jersey.



Dec. 17, 2015 :  Kitov Pharmaceuticals Reports Additional Data from its Phase III Trial on the Beneficial Blood Pressure Effects of KIT-302

November 20, 2015 : Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing

October 21, 2015 : Kitov Pharma Announces Completion of Patient Recruitment for the Phase III Clinical Trial for KIT-302


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
KTOV News: Report of Foreign Issuer (6-k) 10/03/2016 06:14:22 AM
KTOV News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 09/30/2016 04:47:04 PM
KTOV News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 09/30/2016 04:47:04 PM
KTOV News: Report of Foreign Issuer (6-k) 09/27/2016 10:36:56 AM
KTOV News: Report of Foreign Issuer (6-k) 09/27/2016 09:30:23 AM
#4012  Sticky Note GOOD READ 9/2016 PRESENTATION : http://kitovpharma.inve Sugarplum 09/28/16 12:38:22 PM
#3838  Sticky Note KTOV a very professional report (link inside)-"patient population ash111 09/21/16 04:30:30 PM
#3788  Sticky Note KTOV September 13th DD: Market Cap,Cash,sales prediction,Highlights: ash111 09/14/16 12:58:46 PM
#4633   Good ktov day IMO the third leg 10/21/16 05:35:28 PM
#4632   Momentums building folks... !! stock1ace1 10/21/16 01:10:35 PM
#4631   Ktov + Ktovw **** Green Today :) stock1ace1 10/21/16 01:10:25 PM
#4630   yes, ash! way to go! KTOV - KTOVW kei 10/21/16 12:27:31 PM
#4629   Tase will be back to business as usual ash111 10/21/16 11:59:44 AM
#4627   Again, though, my "feelings" based on a call salgovernale69 10/21/16 09:12:21 AM
#4626   As one of the two on the phone tjguy 10/21/16 09:03:09 AM
#4625   That a licensing deal is more likely tjguy 10/21/16 09:01:03 AM
#4624   Patiently waiting for the whales :) stock1ace1 10/21/16 08:52:37 AM
#4623   Yes that would be nice stock1ace1 10/21/16 08:49:52 AM
#4622   I absolutely agree. Plus those looking for scottsmith 10/21/16 08:48:37 AM
#4621   If no BO, we might get better value LearnToTrade 10/21/16 08:42:31 AM
#4620   Yes and in fairness it's not like Isaac salgovernale69 10/21/16 08:35:34 AM
#4619   They wouldn't need to run the company. scottsmith 10/21/16 08:34:25 AM
#4618   KTOV - $3.87 stock1ace1 10/21/16 08:33:05 AM
#4617   I hope you are wrong. I agreed with LearnToTrade 10/21/16 08:29:08 AM
#4616   The real run has not started yet.... DavidW2 10/21/16 08:21:26 AM
#4615   As one of the two on the phone salgovernale69 10/21/16 07:01:14 AM
#4614   I read it the exact opposite. That scottsmith 10/21/16 06:53:12 AM
#4613   << #KTOV ~ #KTOVW >> NDA news stock1ace1 10/20/16 10:17:18 PM
#4612   Sounds good thanks for your insight stock1ace1 10/20/16 10:14:35 PM
#4611   I wouldn't be surprised if this is a tjguy 10/20/16 10:05:37 PM
#4610   No kidding! scottsmith 10/20/16 08:25:30 PM
#4609   Ceo Interview w/ 2 shareholders "Read" (Revised) Link stock1ace1 10/20/16 08:10:58 PM
#4608   Ash said market cap, not share price. Transfer zj3001 10/20/16 07:27:20 PM
#4607   I certainly hope so but would settle for tmeier 10/20/16 05:37:22 PM
#4606   Agree. When I said a while ago that ash111 10/20/16 04:59:58 PM
#4605   I wouldn't be surprised if this is a scottsmith 10/20/16 04:52:26 PM
#4604   Pretty amazing confirmation about kitov future. I think ash111 10/20/16 04:49:04 PM
#4603   Yep. The revised version is 99 percent scottsmith 10/20/16 03:36:30 PM
#4602   Thanks for posting that scott. Also, just salgovernale69 10/20/16 02:51:08 PM
#4601   Fellow KTOV(W) Investors -- I reached out to scottsmith 10/20/16 02:38:11 PM
#4600   New link for CEO Interview. Guys, Isaac salgovernale69 10/20/16 01:43:12 PM
#4599   See the new link for the interview with $Moneypenny$ 10/20/16 01:43:08 PM
#4598   KTOV ~ $3.86 stock1ace1 10/20/16 08:53:27 AM
#4597   I believe we will see a trend upward BEANPOLE 10/20/16 07:17:02 AM
#4596   They had said 4th Q of 2016 or westeffer 10/20/16 12:29:54 AM
#4595   Thanks for posting this! tjguy 10/19/16 11:58:16 PM
#4594   KTOV Great write up from @BradPittsBrother/@Irish_Fan, who spoke stock1ace1 10/19/16 08:04:11 PM
#4593   Nice close guys :D stock1ace1 10/19/16 07:03:26 PM
#4592   got it. thanks. ash111 10/19/16 04:24:52 PM
#4591   200MA is 3.75 50 is about 3.33 and Rymankoly 10/19/16 04:21:20 PM
#4590   Broke both 50-period and 200-period ash111 10/19/16 04:15:01 PM
#4589   Right on, thank you for insight. TradeFlow 10/19/16 04:08:21 PM
#4588   Not yet, we need the 50 EMA to Rymankoly 10/19/16 04:06:32 PM
#4587   congratulations, closed Above 3.8, we have a golden cross. ash111 10/19/16 04:01:19 PM
#4586   Really nice fundamental comparison! Appreciate it! Thanks ash EnricoMania 10/19/16 03:51:15 PM
#4585   I posted this a while ago-and still thinking ash111 10/19/16 03:22:26 PM
#4584   Thanks guys for sharing all! EnricoMania 10/19/16 02:35:12 PM
#4583   It was very reassuring to me to hear salgovernale69 10/19/16 02:14:24 PM